Introduction Annexin-1 (Anx-A1) is an anti-inflammatory protein that plays an important homeostatic role in innate immunity (1-2), however its potential actions in the modulation of adaptive immunity have never been explored. In this study we investigated the role of exogenous and endogenous Anx-A1 in T cell activation and differentiation and its role in the development of Th1/Th2-driven diseases. Results Addition of human recombinant (hr)Anx-A1 to stimulated T cells augmented anti-CD3/CD28-mediated CD25 and CD69 expression and cell proliferation. This effect was paralleled by increased NF-κB, AP-1 and NFAT activation and preceded by a rapid T cell receptor (TCR)-induced externalization of the Anx-A1 receptor. Conversely, analysis of T cell responses in Anx-A1 knock-out cells showed a decrease in cell activation and proliferation as well as in the activation of the above mentioned transcription factors. Interestingly, differentiation of naïve T cells in presence of hrAnx-A1 increased skewing in Th1 cells whereas Anx-A1 deficient T cells demonstrated an increased Th2 phenotype compared to cells from control littermates. In the collagen induced arthritis model (Th1-driven model) treatment of mice with hrAnx-A1 during the immunization phase exacerbated signs and symptoms at disease onset. Consistent with these findings blood CD4+ cells from patients with rheumatoid arthritis showed a marked upregulation of Anx-A1 expression (3). Finally, analysis of allergic response in Anx-A1 knock-out mice using a mouse model of ovalbumin-induced allergic peritonitis (Th2-driven model) demonstrated an exacerbated Th2 response i.e. increased number of T cells and eosinophil at site of inflammation compared to the wild type littermates. Conclusions Together these results demonstrate that Anx-A1 acts as a molecular ‘tuner’ of TCR signalling and suggest this protein might represent a new target for the development of drugs directed to pathologies where an unbalanced Th1/Th2 response or an aberrant activation of T cells is the major etiological factor.
Life Sciences 2007 (2007) Proc Life Sciences, C19
Research Symposium: Annexin-1: a novel target for the therapy of autoimmune diseases
F. D'Acquisto1, N. Paschalidis1, A. L. Sampaio1, G. Rosignoli1, K. Raza2, C. D. Buckley2, R. J. Flower1, M. Perretti1
1. Centre for Biochemical Pharmacology, William Harvey Research Institute, London, United Kingdom. 2. Division of Immunity and Infection, MRC Centre for Immune Regulation University of Birmingham, Birmingham, United Kingdom.
View other abstracts by:
Where applicable, experiments conform with Society ethical requirements.